Literature DB >> 22409940

Exonic deletions of FXN and early-onset Friedreich ataxia.

Mathieu Anheim1, Louise-Laure Mariani, Patrick Calvas, Emmanuel Cheuret, Fabien Zagnoli, Sylvie Odent, Claire Seguela, Cecilia Marelli, Marlène Fritsch, Jean-Pierre Delaunoy, Alexis Brice, Alexandra Dürr, Michel Koenig.   

Abstract

BACKGROUND: Friedreich ataxia (FA) is the most frequent type of autosomal recessive cerebellar ataxia, occurring at a mean age of 16 years. Nearly 98% of patients with FA present with homozygous GAA expansions in the FXN gene. The remaining patients are compound heterozygous for an expansion and a point mutation. Patients who are compound heterozygous for an exonic deletion and an expansion are exquisitely rare.
OBJECTIVES: To describe 6 patients affected with FA due to an exonic deletion mutation (FAexdel) and to compare these 6 patients with FAexdel with 46 patients consecutively diagnosed with typical FA due to homozygous GAA expansion and whose small expansions were within the same range as that of the expansions of the patients with FAexdel.
DESIGN: Description of a series.
SETTING: Academic research. PATIENTS: Six patients with FAexdel and 46 patients with typical FA. INTERVENTION: FXN gene analysis, including assessments of GAA expansion and exon sequencing and determination of exonic copy numbers using multiplex ligation-dependent probe amplification.
RESULTS: We identified 6 patients with FA who presented with the combination of 1 GAA expansion and 1 FXN exonic deletion. The mean (SD) age at onset of the disease was earlier for patients with FAexdel (7 [4] years [range, 3-12 years]) than for patients with typical FA (15 [5] years [range, 6-30 years]) (P = .001), and the median time to confinement to wheelchair was shorter for patients with FAexdel (20 years) than for patients with typical FA (28 years) (P = .002). There was no difference between the mean (SD) size of the expansion for the patients with FAexdel (780 [256] GAA triplet repeat sequences [range, 340-1070 GAA triplet repeat sequences]) and the mean (SD) size of the short expansion for the patients with typical FA (634 [163] GAA triplet repeat sequences [range, 367-1000 GAA triplet repeat sequences]) (P = .10). The mean disease duration before becoming wheelchair bound was shorter for patients with FAexdel (9 years) than for patients with typical FA (13 years), and the incidence of cardiomyopathy was higher for patients with FAexdel (84%) than for patients with typical FA (68%). However, these differences were not significant, probably owing to the small size of the FAexdel group. The other extraneurological signs, such as scoliosis or diabetes mellitus, were particularly frequently observed in the FAexdel group. One patient presented at 9 years of age with severe angina and marked cardiomyopathy that confined her to a wheelchair. Three patients had disabling autonomic disturbances. It appears that exonic deletion significantly contributes to the clinical picture of patients with FA.
CONCLUSIONS: Friedreich ataxia due to an exonic deletion mutation corresponds to an early onset and severe variant of FA. FXN should be investigated for exonic deletion in patients with early-onset FA in which only 1 GAA expansion without a point mutation is found. Patients with FAexdel have to be carefully observed using cardiological, orthopaedic, endocrinological, gastroenterological, and ophthalmological data. Friedreich ataxia due to an exonic deletion mutation should be suspected in young patients presenting with severe scoliosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409940     DOI: 10.1001/archneurol.2011.834

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  17 in total

Review 1.  Milestones in Friedreich ataxia: more than a century and still learning.

Authors:  Agessandro Abrahão; José Luiz Pedroso; Pedro Braga-Neto; Edson Bor-Seng-Shu; Patricia de Carvalho Aguiar; Orlando Graziani Povoas Barsottini
Journal:  Neurogenetics       Date:  2015-02-08       Impact factor: 2.660

2.  High-throughput immunoassay for the biochemical diagnosis of Friedreich ataxia in dried blood spots and whole blood.

Authors:  Devin Oglesbee; Charles Kroll; Oleksandr Gakh; Eric C Deutsch; David R Lynch; Ralitza Gavrilova; Silvia Tortorelli; Kimiyo Raymond; Dimitar Gavrilov; Piero Rinaldo; Dietrich Matern; Grazia Isaya
Journal:  Clin Chem       Date:  2013-07-09       Impact factor: 8.327

3.  Personality and Neuropsychological Profiles in Friedreich Ataxia.

Authors:  Sabrina Sayah; Jean-Yves Rotgé; Hélène Francisque; Marcela Gargiulo; Virginie Czernecki; Damian Justo; Khadija Lahlou-Laforet; Valérie Hahn; Massimo Pandolfo; Antoine Pelissolo; Philippe Fossati; Alexandra Durr
Journal:  Cerebellum       Date:  2018-04       Impact factor: 3.847

4.  Friedreich ataxia is not only a GAA repeats expansion disorder: implications for molecular testing and counselling.

Authors:  Dorota Hoffman-Zacharska; Tomasz Mazurczak; Tomasz Zajkowski; Renata Tataj; Paulina Górka-Skoczylas; Katarzyna Połatyńska; Łukasz Kępczyński; Mariusz Stasiołek; Jerzy Bal
Journal:  J Appl Genet       Date:  2016-02-23       Impact factor: 3.240

5.  Recessive spinocerebellar ataxia with paroxysmal cough attacks: a report of five cases.

Authors:  Luis Velázquez-Pérez; Rigoberto González-Piña; Roberto Rodríguez-Labrada; Raul Aguilera-Rodríguez; Lourdes Galicia-Polo; Yaimeé Vázquez-Mojena; Ana M Cortés-Rubio; Marla R Trujillo-Bracamontes; Cesar M Cerecedo-Zapata; Oscar Hernández-Hernández; Bulmaro Cisneros; Jonathan J Magaña
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

Review 6.  Iron-sulfur cluster biogenesis in mammalian cells: New insights into the molecular mechanisms of cluster delivery.

Authors:  Nunziata Maio; Tracey A Rouault
Journal:  Biochim Biophys Acta       Date:  2014-09-19

7.  Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene.

Authors:  Francesco Saccà; Angela Marsili; Giorgia Puorro; Antonella Antenora; Chiara Pane; Alessandra Tessa; Pasquale Scoppettuolo; Claudia Nesti; Vincenzo Brescia Morra; Giuseppe De Michele; Filippo M Santorelli; Alessandro Filla
Journal:  J Neurol       Date:  2012-11-30       Impact factor: 4.849

8.  Friedreich ataxia in Norway - an epidemiological, molecular and clinical study.

Authors:  Iselin Marie Wedding; Mette Kroken; Sandra Pilar Henriksen; Kaja Kristine Selmer; Torunn Fiskerstrand; Per Morten Knappskog; Tone Berge; Chantal M E Tallaksen
Journal:  Orphanet J Rare Dis       Date:  2015-09-04       Impact factor: 4.123

9.  Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy.

Authors:  Chiranjeevi Sandi; Sahar Al-Mahdawi; Mark A Pook
Journal:  Genet Res Int       Date:  2013-02-19

10.  Frataxin levels in peripheral tissue in Friedreich ataxia.

Authors:  Michael Lazaropoulos; Yina Dong; Elisia Clark; Nathaniel R Greeley; Lauren A Seyer; Karlla W Brigatti; Carlton Christie; Susan L Perlman; George R Wilmot; Christoper M Gomez; Katherine D Mathews; Grace Yoon; Theresa Zesiewicz; Chad Hoyle; Sub H Subramony; Alicia F Brocht; Jennifer M Farmer; Robert B Wilson; Eric C Deutsch; David R Lynch
Journal:  Ann Clin Transl Neurol       Date:  2015-07-01       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.